Details for Patent: 4,866,168

Summary for Patent: 4,866,168

Title:	Hematoporphyrin derivatives and process of preparing
Abstract:	To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs: (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophyllic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C68H70N8O11 or C68H66N8O11Na4. Neoplastic tissue retains the drug after it has cleared normal tissues and illumination results in necrosis. Moreover, other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophlic.
Inventor(s):	Thomas J. Dougherty, William R. Potter, Kenneth R. Weishaupt
Assignee:	Health Research Inc
Application Number:	US06/889,829
Patent Claim Types: see list of patent claims	Use; Composition;

United States Patent 4,866,168: Scope, Claims, and Landscape

United States Drug Patent US 4,866,168 is directed to a process for preparing an aqueous composition enriched in high molecular weight (≥10 kDa) aggregates of fluorescent, photosensitizing porphyrin material (hematoporphyrin derivative, “HpD”), coupled to tumor retention/localization. The operative process levers are (i) acid preparation chemistry (HpH hydrochloride treated with acetic acid + sulfuric acid), (ii) controlled pH elevation to 6.5-12 to drive aggregate formation of 10 kDa or greater, and (iii) selective separation of the resulting aggregates (by filtration retaining >10,000 MW fraction or by affinity/reverse-phase chromatography under specified conditions). Claim 10 is a process-by-composition claim covering the composition prepared by the claimed process.

---

What is the core inventive concept in US 4,866,168?

The patent’s scope centers on producing an aggregate-rich porphyrin mixture with properties tied to photosensitization and tumor retention:

• Starting material: hematoporphyrin hydrochloride (“hematoporphyrin derivative preparation has been prepared by treating hematoporphyrin hydrochloride with a mixture of acetic acid and sulfuric acid”).
• Aggregate formation: “raising the pH of a hematoporphyrin derivative preparation in aqueous medium to 6.5-12 to obtain aggregates of 10 kD or greater.”
• Aggregate isolation: “separating said aggregates from the remainder” of the preparation, with multiple dependent paths:
  • Filtration retaining aggregates above 10,000 molecular weight.
  • Affinity chromatography on a reverse phase medium using specified solvents/conditions (C18; THF use; specified elution sequence; recovery tied to “fourth component eluted as shown in FIG. 5”).
• Performance linkage (composition purpose): aggregates are “fluorescent, photosensitizing, and capable of localizing and being retained in tumor cells for a longer time than normal tissues.”

This combination makes the patent more than a generic “pH precipitation” approach: it ties aggregate formation to a defined HpD preparation route and defines how the ≥10 kDa fraction is isolated.

---

How do the independent and dependent claims define scope?

Claim 1 (independent): Process to make ≥10 kDa tumor-retaining porphyrin aggregates

Claim 1 requires all of the following:

1. HpD preparation step: hematoporphyrin hydrochloride treated with a mixture of acetic acid and sulfuric acid (preparatory chemistry constraint).
2. Aggregate formation step: raise pH of the HpD preparation in aqueous medium to 6.5-12.
3. Aggregate spec: product must contain “aggregates of 10 kD or greater.”
4. Separation step: separate aggregates from remainder of HpD preparation.
5. Resulting aggregate properties (intended/functional characterization):
   • fluorescent
   • photosensitizing
   • localizes and is retained in tumor cells longer than normal tissues.

Key scope boundaries created by Claim 1:

• pH must be within 6.5-12. Lower pH outside range does not meet claim scope.
• Aggregate size cutoff must be ≥10 kDa. Aggregates below 10 kDa do not meet the claim requirement.
• Separation is mandatory. The claim is a process requiring enrichment/isolation, not just aggregate formation.
• Preparatory HpD chemistry is mandatory. The HpD precursor is not generic; it must be made by treating HpH hydrochloride with acetic acid + sulfuric acid.

Claim 2: preferred pH

• Narrows Claim 1 pH “approximately 9.5.”
• This is a dependent narrowing that captures a more specific operational window.

Claim 3-5: filtration-based separation

• Claim 3: separation by filtering that retains aggregates of MW above 10,000.
• Claim 4: maintains pH 6.5-12 during filtration.
• Claim 5: maintains pH approximately 9.5 during filtration.

Scope impact:

• Filtration must be configured so that retention corresponds to >10,000 MW aggregates.
• The pH must be controlled during filtration, not just prior to it.

Claim 6-8: chromatography-based separation

• Claim 6: separation by affinity chromatography.
• Claim 7: chromatography is on a reverse phase column with 5 micron spheres, using THF as solvent.
• Claim 8: reverse phase column is a C18 column; elution sequence:
  • methanol:water:acetic acid (20:5:1), then
  • tetrahydrofuran:water (4:1),
  • and the “porphyrin mixture recovered corresponds to the fourth component eluted as shown in FIG. 5.”

Scope impact:

• These dependent claims lock in substantial specificity (C18, 5 micron spheres, THF use, solvent ratios, elution scheme, and which fraction is recovered).
• Practical enforcement risk increases for defendants practicing these exact operational conditions or substantially equivalents; scope is tighter than filtration route.

Claim 9: specific HpD preparation route

Claim 9 does not change the aggregate formation/separation architecture; it narrows the precursor chemistry details to:

1. Add first mixture of acetic acid + sulfuric acid to hematoporphyrin hydrochloride.
2. Stir one hour to obtain a second mixture.
3. Add second mixture to solution of 5% sodium acetate to obtain a red precipitate.
4. Recover the red precipitate.

Scope impact:

• It narrows the “prepared by treating … with acetic acid and sulfuric acid” limitation into a specific sequence and intermediate steps (stir time, sodium acetate concentration, red precipitate recovery).

Claim 10: composition prepared by Claim 1

• A composition “prepared by the process of claim 1.”

Scope impact:

• Claim 10 captures the aggregate-containing composition defined by the Claim 1 process, even if the end-user does not replicate upstream exact steps, depending on how infringement is proven under process-by-composition frameworks.

---

What does the claim language cover operationally (infringement-relevant constraints)?

Aggregate formation and the pH window

• Required pH elevation: 6.5-12 in aqueous medium.
• Optionally preferred pH: approximately 9.5 (Claims 2 and 5).

Aggregate size specification

• Minimum aggregate size: 10 kD or greater (Claim 1).
• Filtration retention spec: “above 10,000” MW (Claims 3-5). This matches the 10 kDa threshold.

Separation modality is limiting

Two main exclusive-by-dependent-paths:

1. Filtration route (Claims 3-5)

   • Must be configured to retain >10,000 MW aggregates.
   • pH must be maintained during filtration (6.5-12, or ~9.5 per dependent claims).

2. Chromatography route (Claims 6-8)

   • Must be affinity chromatography on reverse phase materials.
   • Specific implementation: reverse phase, C18, 5 micron spheres, THF use, and defined elution sequence.
   • Recovery is constrained to “fourth component” in a figure.

Precursor chemistry is limiting

• HpD precursor must be prepared by treating hematoporphyrin hydrochloride with acetic acid + sulfuric acid.
• Claim 9 narrows this with a timed mixing and precipitation method using 5% sodium acetate.

---

How does the dependent claim structure affect enforcement and design-around?

Enforcement leverage

A claimant can target multiple infringement theories aligned to downstream processing choices:

• Parties using pH elevation to form ≥10 kDa aggregates from the specified HpD precursor and then separating aggregates could fall into Claim 1 and Claim 10.
• Parties using filtration to retain >10,000 MW while maintaining pH during filtration could trigger Claims 3-5.
• Parties isolating by C18 reverse-phase under the specified THF-containing and elution schedules could trigger Claims 6-8.
• Parties using the specific timed acetic/sulfuric acid mixing and sodium acetate precipitation procedure could trigger Claim 9 in addition to Claim 1 structure.

Design-around pressure points

The tightest constraints that can support design-arounds are:

• Precursor route change: using a different hematoporphyrin derivative preparation route could avoid the “prepared by treating… with acetic acid and sulfuric acid” requirement (depending on how strictly courts interpret “prepared by”).
• Aggregate size target: producing aggregates below 10 kDa avoids Claim 1’s explicit aggregate size requirement.
• pH regime shift: operating outside 6.5-12, including avoiding the ~9.5 window, can reduce Claim 1 coverage.
• Separation method change: using a separation process not matching filtration retention above 10,000 MW or not meeting affinity chromatography characteristics (as constrained by dependent claims) can avoid dependent claims while still risking Claim 1 if aggregate formation and “separating said aggregates” is still performed within Claim 1’s broad separation language.

---

What is the practical scope of Claim 10 (composition coverage)?

Claim 10 is a composition claim limited by the process of Claim 1. It covers “a composition prepared by the process of claim 1,” which in practice ties composition infringement to showing the composition has:

• aggregate size distribution consistent with ≥10 kDa aggregates, and
• functional characteristics described in Claim 1 (fluorescent/photosensitizing and tumor localization/retention longer than normal tissue),
• while also tying composition provenance to the Claim 1 defined precursor chemistry and pH-driven aggregation/separation.

For portfolio and freedom-to-operate (FTO) analysis, the primary takeaway is that Claim 10 can be asserted at the composition level even if a user argues they do not follow the precise upstream steps, so long as the accused composition is demonstrably “prepared by” the Claim 1 process or is the same as that process’s product.

---

Where does this patent sit in a broader hematoporphyrin derivative (HpD) / PDT landscape?

US 4,866,168 fits into the Photosensitive Tumor Retention (PDT/photodynamic diagnosis) ecosystem where hematoporphyrin derivatives are used for tumor-localizing photosensitizers. This patent narrows in on:

• a specific aggregate-size enriched fraction (≥10 kDa aggregates),
• made via a specific chemical preparation (HpH treated with acetic acid + sulfuric acid),
• driven by pH-induced aggregation (6.5-12),
• and enriched via size- or fraction-selective separation (filtration retaining >10,000 MW or reverse-phase chromatography with defined solvents and recovery fraction).

In business terms, it is best viewed as a manufacturing-enrichment patent focused on controlling the aggregate profile rather than discovering a new porphyrin molecule.

---

Claim-by-claim scope map (quick reference)

Claim	Category	Mandatory elements (high-level)	Scope width
1	Independent process	HpH treated with acetic acid + sulfuric acid; raise pH 6.5-12 in aqueous medium to form ≥10 kDa aggregates; separate aggregates from remainder; aggregates fluorescent/photosensitizing; tumor localization and retention longer than normal tissue	Broadest within the set; defines the whole manufacturing concept
2	Dependent	pH approximately 9.5	Narrow
3	Dependent	separation by filtration retaining aggregates MW >10,000	Narrow-to-medium
4	Dependent	maintain pH 6.5-12 during filtration	Narrow
5	Dependent	maintain pH approximately 9.5 during filtration	Narrow
6	Dependent	separation by affinity chromatography	Narrow-to-medium
7	Dependent	reverse phase column; 5 micron spheres; THF solvent	Narrow
8	Dependent	C18; elution methanol:water:acetic acid (20:5:1) then THF:water (4:1); recover “fourth component” (FIG. 5)	Narrowest
9	Dependent	specific HpD preparation: 1st acid mixture added, stir 1 hour; add to 5% sodium acetate to precipitate red; recover precipitate	Narrows precursor chemistry
10	Independent composition-by-process	composition prepared by Claim 1 process	Product-level coverage tied to Claim 1

---

Key Takeaways

• US 4,866,168 is an aggregate-enrichment process patent for hematoporphyrin derivative material, requiring ≥10 kDa aggregates formed by pH elevation (6.5-12) and then separated from the remainder.
• Claim 1 is the central anchor: it requires not only pH-driven aggregation and separation, but also a specific HpD precursor chemistry (HpH treated with acetic acid + sulfuric acid).
• Dependent claims create two main enforcement tracks: filtration retaining >10,000 MW fractions and reverse-phase C18 affinity chromatography with defined solvents and recovery fraction.
• Claim 10 covers the resulting composition “prepared by” the Claim 1 process, enabling composition-level claims tied to manufacturing identity.

---

FAQs

1) Is the patent limited to 9.5 pH or does it cover a wider range?

It covers pH 6.5-12 in Claim 1. pH ~9.5 is a dependent narrowing in Claims 2 and 5.

2) What is the minimum aggregate size required for coverage?

Claims require aggregates of 10 kD or greater (Claim 1) and, for filtration, aggregates retained corresponding to molecular weight above 10,000 (Claims 3-5).

3) Does the patent require a specific separation method?

Claim 1 requires separating the aggregates, but dependent claims constrain methods:

• Filtration retaining >10,000 MW (Claims 3-5)
• Affinity chromatography on reverse phase under defined C18/THF/elution conditions (Claims 6-8).

4) What role does the acetic acid/sulfuric acid step play?

It is a mandatory precursor preparation limitation: the HpD preparation must be made by treating hematoporphyrin hydrochloride with acetic acid and sulfuric acid (Claim 1). Claim 9 further narrows this into a timed and precipitation-based protocol.

5) Does the patent include composition claims or only process claims?

It includes a composition claim: Claim 10 covers “a composition prepared by the process of claim 1.”

---

References

[1] United States Patent and Trademark Office. US 4,866,168. (Patent document; claims provided in the prompt).

Drugs Protected by US Patent 4,866,168

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,866,168

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	53204
Australia	2032283
Australia	4246185
Australia	581840